Corient Private Wealth
BIO icon

Corient Private Wealth’s Bio-Rad Laboratories Class A BIO Stock Holding History

Corient Private Wealth’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$407K Sell
1,387
-38
-3% -$10.8K ﹤0.01% 2373
2026
Q1 		$382K Sell
1,425
-439
-24% -$126K ﹤0.01% 2181
2025
Q4 		$565K Buy
1,864
+434
+30% +$135K ﹤0.01% 1808
2025
Q3 		$401K Buy
1,430
+449
+46% +$122K ﹤0.01% 1938
2025
Q2 		$237K Sell
981
-563
-36% -$133K ﹤0.01% 2127
2025
Q1 		$376K Sell
1,544
-667
-30% -$201K ﹤0.01% 1738
2024
Q4 		$726K Sell
2,211
-452
-17% -$153K ﹤0.01% 1448
2024
Q3 		$891K Buy
2,663
+91
+4% +$28.9K ﹤0.01% 1453
2024
Q2 		$702K Buy
2,572
+356
+16% +$104K ﹤0.01% 1471
2024
Q1 		$766K Buy
2,216
+38
+2% +$12.5K ﹤0.01% 1426
2023
Q4 		$703K Buy
2,178
+220
+11% +$69K ﹤0.01% 1437
2023
Q3 		$702K Sell
1,958
-1,140
-37% -$440K ﹤0.01% 1320
2023
Q2 		$1.17M Sell
3,098
-667
-18% -$271K ﹤0.01% 1093
2023
Q1 		$1.81M Buy
3,765
+609
+19% +$285K ﹤0.01% 876
2022
Q4 		$1.33M Buy
+3,156
New +$1.27M ﹤0.01% 826

Other funds holding BIO

First Eagle Investment Management
First Eagle Investment Management New York $60.8B AUM 26.63% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AI
Ariel Investments Chicago, Illinois $10B AUM 42.59% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
EARNEST Partners
EARNEST Partners Atlanta, Georgia $27.7B AUM 52.44% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Corient Private Wealth's BIO Position: Q2 2026 in Review

Corient Private Wealth reduced its Bio-Rad Laboratories Class A (BIO) stake by 2.7% in Q2 2026, selling an estimated $10.8K and leaving 1,387 shares worth $407K. The position accounts for ﹤0.01% of the portfolio, ranked #2373.

Corient Private Wealth first reported a position in BIO in Q4 2022 and has held it in 15 quarters since. The position peaked at $1.81M in Q1 2023. 398 funds tracked by Wall St. Rank hold BIO as of Q2 2026.

  • Corient Private Wealth held 1,387 shares of Bio-Rad Laboratories Class A worth $407K as of Q2 2026.
  • Corient Private Wealth sold 38 Bio-Rad Laboratories Class A shares in Q2 2026, an estimated $10.8K.
  • Bio-Rad Laboratories Class A made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #2373 holding.
  • Corient Private Wealth first reported a position in Bio-Rad Laboratories Class A in Q4 2022 and has held it in 15 quarters since.
  • Corient Private Wealth's Bio-Rad Laboratories Class A position peaked at $1.81M in Q1 2023.
  • 398 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.